User login
Key clinical point: Improvement in the Disease Activity Index in PsA (DAPSA) scores as early as week 8 was associated with a lower progression of structural joint damage at 2 years in biologic-naive patients with psoriatic arthritis (PsA) who were treated with guselkumab.
Major finding: A greater improvement in DAPSA scores as early as week 8 (parameter estimate [β] −0.03, P = .0096) and the achievement of DAPSA low disease activity at week 8 (least squares mean difference −1.44; P = .0151) were associated with a significantly lower radiographic progression of joint damage through week 100.
Study details: This post hoc analysis included 449 biologic-naive patients with PsA from the DISCOVER-2 trial who received 100 mg guselkumab every 4 or 8 weeks.
Disclosures: The DISCOVER-2 trial was funded by Janssen Research & Development, LLC. Five authors declared being employees of Janssen or owning stock or stock options in Johnson & Johnson. The other authors declared ties with various sources, including Janssen.
Source: Mease PJ et al. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2023 (Oct 3). doi: 10.1007/s10067-023-06745-y
Key clinical point: Improvement in the Disease Activity Index in PsA (DAPSA) scores as early as week 8 was associated with a lower progression of structural joint damage at 2 years in biologic-naive patients with psoriatic arthritis (PsA) who were treated with guselkumab.
Major finding: A greater improvement in DAPSA scores as early as week 8 (parameter estimate [β] −0.03, P = .0096) and the achievement of DAPSA low disease activity at week 8 (least squares mean difference −1.44; P = .0151) were associated with a significantly lower radiographic progression of joint damage through week 100.
Study details: This post hoc analysis included 449 biologic-naive patients with PsA from the DISCOVER-2 trial who received 100 mg guselkumab every 4 or 8 weeks.
Disclosures: The DISCOVER-2 trial was funded by Janssen Research & Development, LLC. Five authors declared being employees of Janssen or owning stock or stock options in Johnson & Johnson. The other authors declared ties with various sources, including Janssen.
Source: Mease PJ et al. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2023 (Oct 3). doi: 10.1007/s10067-023-06745-y
Key clinical point: Improvement in the Disease Activity Index in PsA (DAPSA) scores as early as week 8 was associated with a lower progression of structural joint damage at 2 years in biologic-naive patients with psoriatic arthritis (PsA) who were treated with guselkumab.
Major finding: A greater improvement in DAPSA scores as early as week 8 (parameter estimate [β] −0.03, P = .0096) and the achievement of DAPSA low disease activity at week 8 (least squares mean difference −1.44; P = .0151) were associated with a significantly lower radiographic progression of joint damage through week 100.
Study details: This post hoc analysis included 449 biologic-naive patients with PsA from the DISCOVER-2 trial who received 100 mg guselkumab every 4 or 8 weeks.
Disclosures: The DISCOVER-2 trial was funded by Janssen Research & Development, LLC. Five authors declared being employees of Janssen or owning stock or stock options in Johnson & Johnson. The other authors declared ties with various sources, including Janssen.
Source: Mease PJ et al. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2023 (Oct 3). doi: 10.1007/s10067-023-06745-y